Cytotoxic Effect of Disulfiram/copper on Human Cervical Cancer Cell Lines and LGR5-positive Cancer Stem-like Cells

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 May 9

PMID 35534815

Authors

Hao-Zhe Cao

Wen-Ting Yang

Peng-Sheng Zheng

Affiliations

Soon will be listed here.

Abstract

Background: Tumor resistance is a global challenge for tumor treatment. Cancer stem cells (CSCs) are the main population of tumor cells for drug resistance. We have reported that high aldehyde dehydrogenase (ALDH) activity represents a functional marker for cervical CSCs. Here, we aimed at disulfiram (DSF), an ALDH inhibitor, that has the potential to be used for cervical cancer treatment.

Methods: MTT assay, western blot, vector construction and transfection, cell sorting and in vivo anti-tumor assays were performed using cervical cancer cell lines SiHa and HeLa. Cell cycle distribution and cell apoptosis were carried out by flow cytometry. The cytotoxicity of DSF was detected by MTT assay and cervical cancer xenograft models.

Results: DSF was cytotoxic to cervical cancer cell lines in a copper (Cu)-dependent manner. Disulfiram/copper (DSF/Cu) complex induced deregulation of S-phase and inhibited the expression of stemness markers in cervical cancer cells. Furthermore, DSF/Cu could also reduce the cancer stem cell-like LGR5 cells which lead to cisplatin resistance in cervical cancer cells. DSF/Cu complex had the greater antitumor efficacy on cervical cancer than cisplatin in vitro and in vivo.

Conclusion: Our findings indicate that the cytotoxicity of DSF/Cu complex may be superior to cisplatin because of targeting LGR5-positive cervical cancer stem-like cells in cervical cancer. Thus, the DSF/Cu complex may represent a potential therapeutic strategy for cervical cancer patients.

Citing Articles

Review to Elucidate the Correlation between Cuproptosis-Related Genes and Immune Infiltration for Enhancing the Detection and Treatment of Cervical Cancer.

Pandey P, Ramniwas S, Pandey S, Lakhanpal S, Padmapriya G, Mishra S Int J Mol Sci. 2024; 25(19).

PMID: 39408933 PMC: 11477161. DOI: 10.3390/ijms251910604.

Copper homeostasis and cuproptosis in gynecological cancers.

Huang X, Lian M, Li C Front Cell Dev Biol. 2024; 12:1459183.

PMID: 39386020 PMC: 11461353. DOI: 10.3389/fcell.2024.1459183.

Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives.

Zhang C, Huang T, Li L J Hematol Oncol. 2024; 17(1):68.

PMID: 39152464 PMC: 11328505. DOI: 10.1186/s13045-024-01589-8.

Cuproptosis in cancer: biological implications and therapeutic opportunities.

Li L, Zhou H, Zhang C Cell Mol Biol Lett. 2024; 29(1):91.

PMID: 38918694 PMC: 11201306. DOI: 10.1186/s11658-024-00608-3.

Disulfiram: A novel repurposed drug for cancer therapy.

Zeng M, Wu B, Wei W, Jiang Z, Li P, Quan Y Chin Med J (Engl). 2024; 137(12):1389-1398.

PMID: 38275022 PMC: 11188872. DOI: 10.1097/CM9.0000000000002909.

References

Liu G, Frank N, Bartsch H, Lin J . Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos/c-jun, and p53 proteins. Mol Carcinog. 1998; 22(4):235-46. DOI: 10.1002/(sici)1098-2744(199808)22:4<235::aid-mc5>3.0.co;2-i. View

Bhadhprasit W, Kodama H, Fujisawa C, Hiroki T, Ogawa E . Effect of copper and disulfiram combination therapy on the macular mouse, a model of Menkes disease. J Trace Elem Med Biol. 2012; 26(2-3):105-8. DOI: 10.1016/j.jtemb.2012.05.002. View

Nagai M, Vo N, Ogawa L, Chimmanamada D, Inoue T, Chu J . The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med. 2012; 52(10):2142-50. DOI: 10.1016/j.freeradbiomed.2012.03.017. View

Skrott Z, Mistrik M, Andersen K, Friis S, Majera D, Gursky J . Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017; 552(7684):194-199. PMC: 5730499. DOI: 10.1038/nature25016. View

Rae C, Tesson M, Babich J, Boyd M, Sorensen A, Mairs R . The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells. J Nucl Med. 2013; 54(6):953-60. DOI: 10.2967/jnumed.112.113324. View

Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V . High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009; 15(19):6070-8. DOI: 10.1158/1078-0432.CCR-09-1035. View

He H, Markoutsa E, Li J, Xu P . Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly. Acta Biomater. 2018; 68:113-124. PMC: 5803356. DOI: 10.1016/j.actbio.2017.12.023. View

Baffoe C, Nguyen N, Boyd P, Wang W, Morris M, McConville C . Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer. J Pharm Pharmacol. 2014; 67(2):189-98. DOI: 10.1111/jphp.12330. View

Abidin I, Rezoagli E, Simonassi-Paiva B, Fehrenbach G, Masterson K, Pogue R . A Bilayer Vaginal Tablet for the Localized Delivery of Disulfiram and 5-Fluorouracil to the Cervix. Pharmaceutics. 2020; 12(12). PMC: 7762309. DOI: 10.3390/pharmaceutics12121185. View

10.

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

11.

Rassy Carneiro S, Fagundes M, do Rosario P, Neves L, Souza G, Pinheiro M . Five-year survival and associated factors in women treated for cervical cancer at a reference hospital in the Brazilian Amazon. PLoS One. 2017; 12(11):e0187579. PMC: 5690614. DOI: 10.1371/journal.pone.0187579. View

12.

Cvek B . Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram). Drug Discov Today. 2011; 17(9-10):409-12. DOI: 10.1016/j.drudis.2011.12.010. View

13.

Liu X, Wang L, Cui W, Yuan X, Lin L, Cao Q . Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells. Oncotarget. 2016; 7(36):58516-58530. PMC: 5295448. DOI: 10.18632/oncotarget.11305. View

14.

Tesson M, Anselmi G, Bell C, Mairs R . Cell cycle specific radiosensitisation by the disulfiram and copper complex. Oncotarget. 2017; 8(39):65900-65916. PMC: 5630381. DOI: 10.18632/oncotarget.19539. View

15.

Butcher K, Kannappan V, Kilari R, Morris M, McConville C, Armesilla A . Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line. BMC Cancer. 2018; 18(1):753. PMC: 6054747. DOI: 10.1186/s12885-018-4617-x. View

16.

Skinner M, Lahmek P, Pham H, Aubin H . Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014; 9(2):e87366. PMC: 3919718. DOI: 10.1371/journal.pone.0087366. View

17.

Wiggins H, Wymant J, Solfa F, Hiscox S, Taylor K, Westwell A . Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. Biochem Pharmacol. 2015; 93(3):332-42. PMC: 4318799. DOI: 10.1016/j.bcp.2014.12.014. View

18.

Jin N, Zhu X, Cheng F, Zhang L . Disulfiram/copper targets stem cell-like ALDH population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway. J Cell Biochem. 2018; 119(8):6882-6893. DOI: 10.1002/jcb.26885. View

19.

Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S . Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram. Nanotechnology. 2014; 25(12):125102. DOI: 10.1088/0957-4484/25/12/125102. View

20.

Inoue K, Fukunaga M, YAMASAWA K . Effect of disulfiram and its reduced metabolite, diethyl-dithiocarbamate on aldehyde dehydrogenase of human erythrocytes. Life Sci. 1982; 30(5):419-24. DOI: 10.1016/0024-3205(82)90457-x. View